HUMA Humacyte, Inc.
Executive Summary
A strong institutional cluster formed in HUMA during 2024-Q3, with 15 buyers accumulating $10.9M in holdings (net +$6.4M) against just 3 sellers trimming $2.1M. The buying was dominated by active asset managers and a major quant fund (Voloridge added $3.6M, over 30% of all buying), suggesting a shared catalyst thesis around Humacyte's ATEV clinical/commercial progress. The signal is directionally bullish but tempered by the 45-day reporting lag and the stock's high volatility (T+20 alpha +2.16% on prior calls).
Key Financial Metrics
Institutional Positions
Net institutional flow: $4.4M
▲ Buyers (15)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Voloridge Investment Management | ADD | +83.3% | $6.9M | $3.6M |
| Rafferty Asset Management | DOUBLED | +136.8% | $1.3M | $843.0K |
| Citadel | DOUBLED | +248.8% | $833.0K | $622.0K |
| Verition Fund Management | DOUBLED | +459.1% | $491.0K | $413.0K |
| Victory Capital Management | DOUBLED | +551.6% | $418.0K | $362.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| D.E. Shaw | TRIM | -72.9% | $2.8M | -$1.9M |
| Alliancebernstein | TRIM | -31.2% | $457.0K | -$100.7K |
| Russell Investments Group | NEAR_EXIT | -90.7% | $2.0K | -$1.6K |
Actionable Insight
The cluster's active-manager dominance and >$6M in fresh buying suggests a shared thesis around ATEV regulatory/commercial catalysts. However, the 45-day 13F lag means positions may already be partially reduced. Monitor upcoming ATEV-related regulatory or clinical milestones for catalyst timing. D.E. Shaw's large trim is a contrarian flag — watch for any negative data or insider selling in subsequent filings.
Key Facts
- 15 institutional buyers vs 3 sellers in Q3 2024
- Net institutional accumulation of ~$6.4M (total buyer holdings $10.9M vs seller reductions of $2.1M)
- Voloridge Investment Management was the largest buyer, adding $3.6M (83% increase to $6.9M position)
- Rafferty Asset Management doubled its stake to $1.3M (+$843K)
- Citadel doubled its position (+$622K) for a $833K total
- D.E. Shaw was the largest seller, trimming 73% of its stake (-$1.95M) to $863K
- Dominance by active managers suggests a catalyst-driven thesis rather than passive rebalancing
Financial Impact
Net institutional buying of ~$4.4M (total buyer inflows of ~$6.4M minus seller outflows of ~$2.1M) into HUMA during Q3 2024
Risk Factors
- 13F data lags 45 days — bulk of buying may have been already unwound or rotated
- Single-fund concentration: Voloridge alone accounts for ~56% of total buyer holdings ($6.9M of $10.9M)
- D.E. Shaw's 73% trim signals potential informed selling by a sophisticated quant fund
- HUMA's high volatility (prior T+5 moves of -32% to +29%) amplifies both upside and downside risk
- Pre-commercial biotech with binary regulatory risk (any ATEV setback could reverse accumulation)
- Insider activity is mixed (2 buys $60K, 2 sells $82K) — no clear alignment with the cluster direction
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-HUMA-2024-Q3 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $1.07 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
3d ago
|
8-K
| $1.07 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
4d ago
|
Press Release
| $1.16 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
4d ago
|
Press Release
| $1.16 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 10, 2026
4d ago
|
Press Release
| $1.35 awaiting T+5 | awaiting T+5 | — | — |
|
May 20, 2026
25d ago
|
Insider Cluster
| $1.02 $1.28 | ▲ +25.49% | ▲ +23.89% | — |
|
May 13, 2026
4w ago
|
Press Release
| $1.13 $0.8250 | ▼ −26.99% | ▼ −25.83% | — |
|
May 8, 2026
5w ago
|
Press Release
| $1.06 $1.00 | ▼ −5.66% | ▼ −7.12% | — |
|
Apr 21, 2026
7w ago
|
Press Release
| $0.6590 $0.8480 | ▲ +28.68% | ▲ +27.60% | — |
|
Mar 23, 2026
11w ago
|
Press Release
| $0.8500 $0.5750 | ▼ −32.35% | ▼ −28.79% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access